What the FDA labels say about taking them together
Carbamazepine and elbasvir/grazoprevir
Elbasvir/grazoprevir's FDA label of March 13, 2026 names carbamazepine in its contraindications section; the carbamazepine labels PlainMeds reads (3) do not name elbasvir/grazoprevir.
Check it at the source: the carbamazepine FDA label on DailyMed (effective August 20, 2026, Novartis Pharmaceuticals Corporation); the elbasvir/grazoprevir FDA label on DailyMed (effective March 13, 2026, Merck Sharp & Dohme LLC).
What does the carbamazepine label say about elbasvir/grazoprevir?
Carbamazepine's label (effective August 20, 2026) and its 2 other brand-application labels do not name elbasvir/grazoprevir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Tegretol), Novartis Pharmaceuticals Corporation, effective August 20, 2026 (SPL set 8d409411-aa9f-4f3a-a52c-fbcb0c3ec053), via openFDA; the full label on DailyMed
What does the elbasvir/grazoprevir label say about carbamazepine?
Elbasvir/grazoprevir label, contraindicationsNamed in a table that the FDA label file prints without its column breaks; the full label shows the table.
Source: FDA drug label (ZEPATIER), Merck Sharp & Dohme LLC, effective March 13, 2026 (SPL set 164dc02a-9180-426a-b8b5-04ab39d2bbd4), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Carbamazepine | Elbasvir/grazoprevir | |
|---|---|---|
| Labeled for | Bipolar disorder, Seizures and epilepsy | Hepatitis C |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.119 per tablet 200 mg tablet | n/a |
| Shortage now | A presentation being discontinued | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once